(0.80%) 5 058.42 points
(0.75%) 38 188 points
(1.34%) 15 814 points
(0.14%) $79.11
(4.87%) $2.03
(0.27%) $2 317.30
(0.65%) $26.92
(1.05%) $964.90
(-0.05%) $0.933
(-0.37%) $10.99
(-0.03%) $0.798
(-1.40%) $91.96
@ $21.69
Išleistas: 14 vas. 2024 @ 16:30
Grąža: -10.60%
Ankstesnis signalas: vas. 13 - 16:30
Ankstesnis signalas:
Grąža: -1.99 %
Live Chart Being Loaded With Signals
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally...
Stats | |
---|---|
Šios dienos apimtis | 184 761 |
Vidutinė apimtis | 645 562 |
Rinkos kapitalizacija | 1.74B |
EPS | $0 ( 2024-02-27 ) |
Kita pelno data | ( $-0.100 ) 2024-06-06 |
Last Dividend | $1.750 ( 2009-07-01 ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.10 |
ATR14 | $0.0260 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-14 | Muzzey Dale | Sell | 940 | Common Stock |
2024-04-14 | Verratti Mark | Sell | 1 076 | Common Stock |
2024-04-06 | Munk Natalie | Sell | 581 | Common Stock |
2024-03-14 | Leffler Scott J. | Buy | 46 905 | Common Stock |
2024-03-25 | Munk Natalie | Sell | 363 | Common Stock |
INSIDER POWER |
---|
52.44 |
Last 96 transactions |
Buy: 1 118 283 | Sell: 407 342 |
Tūris Koreliacija
Myriad Genetics Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Myriad Genetics Inc Koreliacija - Valiuta/Žaliavos
Myriad Genetics Inc Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $678.40M |
Bruto pelnas: | $476.40M (70.22 %) |
EPS: | $-1.390 |
FY | 2022 |
Pajamos: | $678.40M |
Bruto pelnas: | $476.40M (70.22 %) |
EPS: | $-1.390 |
FY | 2021 |
Pajamos: | $690.60M |
Bruto pelnas: | $493.00M (71.39 %) |
EPS: | $-0.350 |
FY | 2020 |
Pajamos: | $638.60M |
Bruto pelnas: | $452.50M (70.86 %) |
EPS: | $-2.69 |
Financial Reports:
No articles found.
Myriad Genetics Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $1.750 | 2009-06-15 |
Last Dividend | $1.750 | 2009-07-01 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $3.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.02 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2009 | $3.50 | 10.20% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.374 | 1.500 | -7.47 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.239 | 1.200 | -7.96 | -9.55 | [0 - 0.3] |
returnOnEquityTTM | -0.350 | 1.500 | -5.00 | -7.49 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.268 | 0.800 | 8.66 | 6.93 | [1 - 3] |
quickRatioTTM | 0.963 | 0.800 | 9.04 | 7.23 | [0.8 - 2.5] |
cashRatioTTM | 0.363 | 1.500 | 9.09 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.175 | -1.500 | 7.08 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -93.79 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.782 | 2.00 | -0.261 | -0.521 | [0 - 30] |
freeCashFlowPerShareTTM | -1.692 | 2.00 | -0.846 | -1.692 | [0 - 20] |
debtEquityRatioTTM | 0.295 | -1.500 | 8.82 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.689 | 1.000 | 1.852 | 1.852 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.370 | 1.000 | -9.41 | -9.41 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.317 | 1.000 | -2.87 | -2.87 | [0.2 - 2] |
assetTurnoverTTM | 0.639 | 0.800 | 9.07 | 7.26 | [0.5 - 2] |
Total Score | -0.0149 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -5.80 | 1.000 | -0.687 | 0 | [1 - 100] |
returnOnEquityTTM | -0.350 | 2.50 | -3.21 | -7.49 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.692 | 2.00 | -0.564 | -1.692 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.782 | 2.00 | -0.261 | -0.521 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0599 | 1.500 | -2.93 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.0870 | 1.000 | -4.68 | 0 | [0.1 - 0.5] |
Total Score | -1.944 |
Myriad Genetics Inc
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.